00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
18:51 , Jun 27, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting EZH2 for colitis and colitis-associated colorectal cancer

DISEASE CATEGORY: Gastrointestinal; cancer INDICATION: Colitis; colorectal cancer Inhibiting EZH2 could help treat colitis and colitis-associated colorectal cancer. The EZH2 inhibitor GSK2816126 or a tool compound EZH2 inhibitor increased survival and colon length, which is...
21:30 , May 30, 2019 |  BC Extra  |  Company News

Epizyme looks to sarcoma for first approval

More than a decade after it was founded and after nearly $1 billion raised, Epizyme has submitted its first NDA to FDA for a small molecule inhibitor of an epigenetic cancer target. The company is...
21:58 , May 24, 2019 |  BioCentury  |  Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
21:51 , Mar 7, 2019 |  BC Extra  |  Financial News

Follow-on roundup: Horizon, Apellis, Epizyme

Horizon, Apellis and Epizyme each priced follow-ons raising a total of $552 million. Horizon Pharma plc (NASDAQ:HZNP) raised $300 million late Wednesday through the sale of 12 million shares at $24.50. The price is a...
16:15 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Scleroderma Patient sample and mouse studies suggest inhibiting EZH2 could help treat scleroderma. In fibroblasts from patients with diffuse cutaneous scleroderma, levels of EZH2 mRNA were higher than in fibroblasts from healthy volunteers. In...
20:33 , Dec 6, 2018 |  BC Innovations  |  Translation in Brief

Opening chromatin: long-term detriment?

An Institute for Research in Biomedicine team has shown increasing chromatin accessibility in cancer could promote tumor aggressiveness, not reduce tumor mutation burden (TMB) as previously thought. The findings, reported last month in Nature Cell...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
19:35 , Oct 5, 2018 |  BC Week In Review  |  Financial News

Epizyme raises $75M follow-on

Epizyme Inc. (NASDAQ:EPZM) raised $75 million on Oct. 2 through the sale of 8.3 million shares at $9 in a follow-on underwritten by Jefferies. The price is a 7% discount to Epizyme’s close of $9.71...
19:09 , Oct 3, 2018 |  BC Extra  |  Financial News

GW, Epizyme, Kala price follow-ons

GW Pharmaceuticals plc (NASDAQ:GWPH), Epizyme Inc. (NASDAQ:EPZM) and Kala Pharmaceuticals Inc. (NASDAQ:KALA) each priced follow-ons late Tuesday, raising a total of $437 million. GW raised $300 million through the sale of 1.9 million ADSs at...